Multi Drug Resistance Tuberculosis: Genesis, Pharmacological Treatment and Ethionamide Drug Profiling

Abstract

Drug-resistant tuberculosis, particularly those with rifampicin resistance (RR-TB), has emerged as one of the major challenges to the goal of eliminating tuberculosis. Additionally, three or four different medications must be used in an effort to treat TB, but sadly, there aren't many treatments that can be said to be truly effective. The term "multidrug-resistant tuberculosis" (MDR-TB) refers to tuberculosis caused by M. tuberculosis that is resistant to the two first-line drugs, rifampicin and isoniazid has considerably increased recently. XDR-TB refers to an MDR-TB infection that is also resistant to a fluoroquinolone and one of the three second-line injectable antibiotics (amikacin, kanamycin, or capreomycin). Fortunately, the noticeable rise of RR-TB cases throughout the world in recent years has encouraged investment in the development of novel TB medications, and other medications under investigation for other illnesses have successfully been tried on TB. In contrast to isoniazid and rifampicin, a combination of medications is used to treat MDR-TB. Fluoroquinolones, aminoglycosides, ethionamide, cycloserine, aminosalicyclic acid, linezolid, and clofazimine are a few of the medications that fall under this category. The occurrence of adverse drug responses should be regularly observed, and treating physicians should be well aware of the risks involved with the use of second-line anti-TB medications. We have gathered data on the safety and tolerability of second-line anti-TB drug ethionamide in this chapter.